Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase 1/2 Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer
Keyword(s):
Phase 1
◽
Keyword(s):
Keyword(s):